Traws Pharma Inc (TRAW)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.86M
Last updated: Nov 17, 2026 at 11:03 AM ET
Traws Pharma Inc (TRAW) Stock Forecast
Analysts expect Traws Pharma (TRAW) to earn -$1.33 per share in the fiscal year ending Dec 31, 2026. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$1.88.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$1.33
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$1.88
- EPS consensus
- Next report
- Apr 13, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$1.33 | -$1.33 to -$1.33 | 1 |
| Dec 31, 2027 | -$1.88 | -$1.88 to -$1.88 | 1 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.24 | -$0.28 to -$0.20 | 4 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.13.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$1.33 | -$1.82 | -$1.82 | -$1.82 | -$3.13 | N/A |
| Fiscal year ending Dec 31, 2027 | -$1.88 | -$1.98 | -$1.98 | -$1.98 | -$4.03 | N/A |
Frequently Asked Questions About TRAW
What is the TRAW stock forecast?
Consensus analyst estimates put Traws Pharma's EPS at -$1.33 for the fiscal year ending Dec 31, 2026.
What EPS do analysts expect from TRAW next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.33, with estimates from -$1.33 to -$1.33 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.88, with estimates from -$1.88 to -$1.88 from 1 analyst.
How many analysts cover TRAW?
1 analyst estimates EPS for Traws Pharma for the fiscal year ending Dec 31, 2026.
TRAW pages: Overview, Earnings, Forecast, Financials, Competitors